New approaches in the therapy of prostate cancer: The role of genetic patterns in selecting targeted treatments
DOI: https://doi.org/10.22591/magyurol.2023.2.fazekast.75
Authors:
Fazekas Tamás dr.1, Dér Bálint dr.1, Csizmarik Anita dr.1, Soós Áron1, Fekete Bálint dr.1, Nyirády Péter dr.1, Szarvas Tibor dr.1,2
1 Semmelweis Egyetem ÁOK, Urológiai Klinika és Andrológiai Centrum, Budapest
2 Duisburg-Esseni Egyetem, Urológiai Klinika, Essen, Németország
Summary
The use of genetic testing for prostate cancer is becoming increasingly common in clinical practice, particularly because of the emergence of PARP inhibitors that target tumours with specific genetic abnormalities in their BRCA and other homologous recombination repair (HRR) genes. At the same time, the number of available therapies that target specific subgroups of prostate cancer based on their genetic makeup is continuously growing. Consequently, the selection of treatment for prostate cancer patients may involve testing multiple genes to allow for more tailored treatment plans that take into account the genetic features of the tumour. In this review we aim to provide an overview on the currently relevant genetic alterations in prostate cancer for therapeutic purposes.